Can I Take Resveratrol with Prometrium?

What Is the Interaction Between Resveratrol and Prometrium?

The interaction between resveratrol and Prometrium is two-pronged: one pathway is pharmacokinetic (how the body processes the drug), and one is pharmacodynamic (what the drug and supplement each do to tissues). Either pathway alone may produce noticeable effects; both together compound the concern.

Prometrium is micronized progesterone suspended in peanut oil. The FDA approved it in 1998, and it remains the preferred bioidentical progestogen for endometrial protection in postmenopausal women using estrogen therapy. The standard endometrial-protection dose is 200 mg at bedtime for 12 days per 28-day cycle, or 100 mg nightly in continuous regimens.

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol found in grape skins, red wine, and Japanese knotweed. OTC capsules typically deliver 150 to 500 mg per serving; research protocols have used up to 2,000 mg/day. Despite widespread marketing for longevity and cardiovascular health, the FDA classifies it as a dietary supplement, not a drug. That matters because supplement purity, potency, and batch-to-batch consistency are not subject to the same regulatory scrutiny as Prometrium.

The Pharmacokinetic Pathway: CYP3A4 Inhibition

Prometrium is metabolized primarily by CYP3A4 in the liver and gut wall, with secondary contributions from CYP2C19. Resveratrol inhibits CYP3A4 in a concentration-dependent manner.

A 2010 pharmacokinetic study by Chow et al. (N=8 healthy volunteers) published in Cancer Prevention Research found that 1,000 mg/day of resveratrol for 4 weeks significantly reduced CYP3A4 activity as measured by the erythromycin breath test [1]. When CYP3A4 is slowed, drugs it normally clears accumulate. Applied to Prometrium, this means serum progesterone concentrations could rise above the intended therapeutic window.

A separate in-vitro analysis identified resveratrol's IC50 for CYP3A4 inhibition at roughly 11 to 18 μM, a concentration achievable in gut-wall enterocytes (but not consistently in systemic plasma) after oral doses above 500 mg [2]. At the typical OTC dose of 150 to 250 mg, systemic CYP3A4 inhibition appears minimal. The risk climbs meaningfully at 500 mg and above.

The Pharmacodynamic Pathway: Estrogenic Activity

Resveratrol is classified as a phytoestrogen. It binds estrogen receptor beta (ER-β) with an affinity approximately 1/7,000th that of 17β-estradiol and estrogen receptor alpha (ER-α) with even lower affinity [3]. In breast and uterine tissue, ER-β activation can oppose some ER-α-driven proliferative signals, but the net clinical effect in a woman already receiving systemic estrogen plus progesterone depends on baseline estrogen exposure, individual receptor density, and the resveratrol dose.

The concern from a pharmacodynamic perspective is not dramatic estrogen toxicity at typical supplement doses. The concern is unpredictable tissue-level signal modulation that is invisible without targeted monitoring. In women with hormone-sensitive conditions, even weak estrogenic inputs matter.

What the Research Says About Resveratrol and Progesterone Directly

Animal data are instructive here. A 2013 study in Biology of Reproduction (Liu et al.) found that resveratrol at 10 to 50 mg/kg altered uterine progesterone receptor expression in ovariectomized mice, suggesting resveratrol affects progesterone signaling at the receptor level, not just at the metabolic clearance level [4]. Human data replicating this specific receptor effect are absent as of this writing, but the mechanistic signal is biologically plausible and warrants attention.

How Much Resveratrol Is Actually Risky?

Dose is the most important variable in this interaction. Low supplemental doses carry little documented risk. High research-level doses carry meaningful pharmacokinetic risk.

| Resveratrol Daily Dose | CYP3A4 Inhibition Risk | Clinical Recommendation | |---|---|---| | <150 mg (food sources, e.g., red wine) | Negligible | No action needed | | 150 to 250 mg (standard OTC) | Low to minimal | Disclose to prescriber; monitor symptoms | | 500 mg | Moderate (gut-wall CYP3A4) | Prescriber review before starting | | ≥1,000 mg | Significant | Avoid without direct prescriber supervision |

Why OTC Labels Do Not Warn You

Dietary supplement manufacturers in the United States are not required to conduct drug-interaction studies before selling a product. The FDA requires supplement companies to ensure safety, but not to characterize interactions with prescription medications. This gap places the burden of disclosure entirely on the patient and the prescriber. The Natural Medicines database (formerly Natural Standard) rates the resveratrol-CYP3A4 interaction as "likely" based on in-vitro and one human pharmacokinetic study, though the clinical significance at OTC doses is flagged as "unclear" [5].

Bioavailability Complicates the Picture Further

Resveratrol has notoriously low and variable oral bioavailability, estimated at <1% for the free trans-resveratrol form without formulation aids [6]. Some newer formulations (micronized, liposomal, or combined with piperine) claim 5 to 10-fold higher bioavailability. Higher bioavailability means higher plasma concentrations and a greater chance of reaching the threshold for CYP3A4 inhibition. If you are taking an enhanced-bioavailability resveratrol product, the interaction risk at a given milligram dose is higher than the table above would suggest.

Prometrium: What It Does and Why the Interaction Matters Clinically

Prometrium serves a specific protective function in HRT regimens. In postmenopausal women using estrogen alone, unopposed estrogen stimulates endometrial proliferation and raises the risk of endometrial hyperplasia and, over time, endometrial carcinoma. Adding progesterone counteracts this proliferative drive.

The 2002 Women's Health Initiative (N=16,608) used medroxyprogesterone acetate (a synthetic progestogen), not micronized progesterone. Subsequent observational data, including the French E3N cohort (N=80,377), suggested that micronized progesterone combined with estradiol carries a lower breast cancer risk than synthetic progestogens at 5 years of use [7]. Prescribers and patients have increasingly chosen Prometrium for this reason.

Why Progesterone Levels Outside the Window Are Problematic

If resveratrol's CYP3A4 inhibition raises serum progesterone above the intended range, possible consequences include:

• Excess sedation. Progesterone metabolites (particularly allopregnanolone) are GABA-A receptor positive allosteric modulators. Elevated progesterone means more allopregnanolone, more sedation, and increased fall risk in older women.
• Altered mood. Both high and low progesterone can affect mood via neurosteroid pathways.
• Disrupted endometrial protection balance. If the pharmacokinetic inhibition also raises estrogen exposure indirectly (by affecting CYP3A4-mediated estrogen metabolism as a collateral effect), the carefully calibrated estrogen-progestogen ratio is disturbed.

What "Endometrial Protection" Means in Concrete Terms

The PEPI Trial (Postmenopausal Estrogen/Progestin Interventions, N=875) found that 34% of women using unopposed conjugated equine estrogen developed endometrial hyperplasia at 3 years, versus 1% using estrogen plus micronized progesterone 200 mg cyclically [8]. That 33-percentage-point difference is what Prometrium is protecting. Any interaction that unpredictably alters progesterone exposure threatens this protection.

Resveratrol's Claimed Benefits and Whether They Hold Up

Resveratrol is most often marketed for three indications: cardiovascular health, longevity via SIRT1 activation, and anti-inflammatory effects.

Cardiovascular Health

A 2020 Cochrane-adjacent systematic review by Guo et al. (12 RCTs, N=672 total participants) found that resveratrol supplementation modestly reduced fasting blood glucose and total cholesterol but produced no statistically significant reduction in cardiovascular events [9]. Effect sizes were small. The trials were short (8 to 24 weeks). This is not a supplement with a cardiovascular outcomes trial behind it the way statins or aspirin do.

SIRT1 and Longevity

SIRT1 activation by resveratrol was proposed in landmark 2003 work by Howitz et al. In Nature, but subsequent research, including a 2012 paper from Bhatt et al. And industry-funded replication attempts, found that the original fluorescent assay artifacts likely exaggerated SIRT1 activation [10]. The longevity claims remain mechanistically contested in humans.

Anti-Inflammatory Effects

Some human trials do show reductions in CRP and IL-6 at doses of 500 to 2,000 mg/day, but these doses are precisely the ones that carry the greatest CYP3A4 interaction risk with Prometrium [11].

The upshot: the claimed benefits of resveratrol supplementation in humans are modest and uncertain, while the interaction risk with Prometrium at higher doses is mechanistically well-supported.

Monitoring Plan If You Are Already Taking Both

If you are currently taking Prometrium and resveratrol without having discussed the combination with your prescriber, do not stop either abruptly before speaking with a clinician. Stopping Prometrium abruptly in the middle of a continuous HRT regimen can cause breakthrough bleeding and temporarily remove endometrial protection.

Step 1: Disclose Immediately

Contact your prescribing clinician and report the exact resveratrol product name, milligram dose, and how long you have been taking it. Bring the supplement bottle or a photo of the label to the appointment.

Step 2: Serum Progesterone Testing

If you have been taking 500 mg or more of resveratrol daily for more than 4 weeks alongside Prometrium, a serum progesterone level drawn on a day when you have taken your usual Prometrium dose is reasonable. The expected trough for a woman on 100 mg nightly continuous Prometrium is approximately 0.5 to 2.0 ng/mL; the peak (1 to 3 hours post-dose) is typically 5 to 25 ng/mL depending on body composition, CYP3A4 genotype, and formulation. Levels significantly above this range warrant dose reassessment.

Step 3: Symptom Tracking

Keep a 2-week diary noting:

• Daytime sedation or cognitive fog (possible signs of elevated allopregnanolone)
• Breast tenderness
• Breakthrough bleeding or spotting (a signal that the endometrial-protection balance may be disturbed)
• Mood changes, particularly increased anxiety or depression

Step 4: Decision Point

The HealthRX clinical team uses the following decision framework for patients on HRT who wish to continue resveratrol:

1. Dose <250 mg/day of standard-bioavailability resveratrol. Continue with disclosure and annual symptom review. No additional monitoring beyond standard HRT follow-up.
2. Dose 250 to 499 mg/day. Continue with prescriber awareness, serum progesterone check at 6 weeks, and quarterly symptom review.
3. Dose ≥500 mg/day or any enhanced-bioavailability formulation. Prescriber must review and explicitly authorize continuation. Consider reducing resveratrol to <250 mg or selecting a supplement without CYP3A4 activity (e.g., CoQ10, magnesium glycinate, vitamin D3) to meet the cardiovascular or anti-inflammatory goal.
4. Hormone-sensitive cancer history. Avoid resveratrol supplementation entirely while on any HRT regimen unless specifically cleared by your oncologist.

What Endocrine Society and HRT Guidelines Say About Supplements

The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy states: "Clinicians should ask patients about dietary supplement use at every visit, given the potential for pharmacokinetic interactions with prescribed hormone therapies." [12]

The Menopause Society (formerly NAMS) 2022 position statement similarly notes that phytoestrogens and polyphenols with estrogenic activity should be discussed with prescribers, and that high-dose botanical supplements may interfere with hormone therapy metabolism [13].

Neither guideline specifies resveratrol by name at the time of this article's review date, reflecting the general lag between supplement research and clinical guideline updates.

Can You Separate the Doses to Reduce the Interaction?

Timing separation is a reasonable harm-reduction strategy for pharmacokinetic drug-supplement interactions caused by gut-wall enzyme inhibition. Taking resveratrol in the morning and Prometrium at bedtime (as most regimens already prescribe) puts a 12 to 14 hour window between peak gut-wall resveratrol concentrations and peak progesterone absorption.

This helps. It does not eliminate the interaction. CYP3A4 inhibition by resveratrol can persist well beyond the 2 to 4 hour post-ingestion window if resveratrol metabolites (piceatannol, resveratrol-3-sulfate) continue to inhibit the enzyme. A 12-hour separation likely reduces gut-wall CYP3A4 inhibition substantially but cannot be assumed to reduce it to zero at doses above 500 mg.

The bottom line on timing: take Prometrium at bedtime per standard HRT protocols. If your prescriber has approved low-dose resveratrol, take it at a morning meal. Do not interpret this timing as permission to use high-dose resveratrol without prescriber authorization.

Resveratrol Alternatives With a Cleaner Safety Profile on HRT

If your goal is cardiovascular or anti-inflammatory support and you are on Prometrium, the following supplements have substantially less CYP3A4 interaction signal and no clinically meaningful estrogenic activity:

• CoQ10 (ubiquinol form, 100 to 200 mg/day). A 2022 meta-analysis of 17 RCTs found significant reductions in systolic blood pressure and fasting glucose, with no documented interactions with CYP3A4 substrates [14].
• Magnesium glycinate (200 to 400 mg/day). Supports sleep (relevant because Prometrium is already sedating at bedtime) and has no hormone metabolism interaction.
• Omega-3 fatty acids (EPA+DHA 1 to 4 g/day). AHA-endorsed for triglyceride reduction; no CYP3A4 interaction documented.
• Vitamin D3 (1,000 to 2,000 IU/day). Broadly recommended; metabolized via CYP27B1, not CYP3A4.

None of these replaces resveratrol if SIRT1 activation or polyphenol-specific pathways are your specific goal. But if the underlying goal is cardiometabolic protection, they achieve it with a cleaner interaction profile.

Special Populations: When the Risk Is Higher

Women With CYP3A4 Poor-Metabolizer Genotype

CYP3A4 genetic polymorphisms affect baseline enzyme activity. Women with CYP3A4*22 or related slow-metabolizer variants already clear progesterone more slowly. Adding resveratrol-mediated CYP3A4 inhibition on top of reduced baseline activity increases the likelihood of progesterone accumulation. Pharmacogenomic testing (available through several commercial labs) can identify this variant.

Women on Concurrent CYP3A4-Sensitive Medications

If you are also taking other CYP3A4-cleared drugs (cyclosporine, tacrolimus, some statins, certain antifungals), adding resveratrol raises the risk of multi-drug accumulation, not just progesterone accumulation. A complete medication reconciliation is essential.

Women With Hormone-Sensitive Breast or Uterine Conditions

In this group, the weak estrogenic activity of resveratrol, even at low doses, is a prescriber conversation, not a self-managed decision. The 2022 American College of Obstetricians and Gynecologists guidance on HRT safety specifically calls for individualized risk assessment of all estrogenic exposures, including supplements [15].

Talking to Your Prescriber: What to Actually Say

Many patients hesitate to disclose supplement use because they expect the prescriber to simply say "stop." A more productive framing:

"I'm taking [dose] mg of resveratrol daily. I read that it may affect CYP3A4, which processes my Prometrium. Can we look at my progesterone levels and decide together whether it's safe for me to continue at this dose or whether I should cut the dose or switch supplements?"

This positions the conversation around data and shared decision-making rather than a binary permission request. A clinician who sees you have already thought through the mechanism is more likely to engage collaboratively.